Exendin-4 inhibiting cyclophilin A reducing the pathological phenotype of atherosclerotic mice

YANG Shan-shan PAN Yu-xiang ZHENG Wan WANG Zheng

Acta Anatomica Sinica ›› 2024, Vol. 55 ›› Issue (2) : 229-236.

PDF(13105 KB)
Welcome to visit Acta Anatomica Sinica! Today is Chinese
PDF(13105 KB)
Acta Anatomica Sinica ›› 2024, Vol. 55 ›› Issue (2) : 229-236. DOI: 10.16098/j.issn.0529-1356.2024.02.015
Histology,Embryology and Developmental Biology

Exendin-4 inhibiting cyclophilin A reducing the pathological phenotype of atherosclerotic mice

  • YANG Shan-shan PAN Yu-xiang ZHENG Wan1*  WANG Zheng1
Author information +
History +

Abstract

Objective To investigate the effect of glucagon-like peptide 1 (GLP-1) receptor agonists exendin-4 on the secretion of cyclophilin A (CyPA) to inhibit atherosclerosis (AS) and vascular calcification in mice role of the process.   Methods Twenty ApoE-/- mice were randomly divided into model group and exendin-4 group, 10 mice in each group, and were fed with high-fat diet to establish AS model, another 10 wild-type C57BL/6J mice were taken as the control group, and the exendin-4 group was intraperitoneally injected with the GLP-1R agonist exendin-4, 1/d, for 8 weeks. After 8 weeks, the ELISA method  was used to determine the level of triglyceride(TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and CyPA, serum calcium level was detected by methylthymol blue colorimetric method, oil red O staining to detect the development of atherosclerotic plaques in the aorta, HE staining was used to observe the pathological changes of the aorta, Von Kossa staining was used to observe the calcium deposition in the aorta, immunohistochemical staining, Real-time PCR and Western blotting were used to detect the expression levels of aortic RUNX2 and bone morphogenetic protein 2(BMP-2), immunofluorescent staining was used to detect the positive expression of CyPA in aortic tissue.   Results Compared with the control group, the serum levels of TG, TC, LDL-C, Ca and CyPA in the model group increased (P<0.05), the atherosclerotic plaque areas of the aorta increased (P<0.05), the aortic wall was thickened significantly and a large number of inflammatory cells were infiltrated, a large amount of calcium deposits were deposited in the aortic parietal membrane, the positive expression area ratio of RUNX2 and BMP-2, the relative mRNA expression of RUNX2 and BMP-2, the relative protein expression of RUNX2 and BMP-2 in aortic tissue all increased (P<0.05), and the red fluorescence of CyPA expression in aortic tissue was enhanced significantly. Compared with the model group, the serum levels of TG, TC, LDL-C, Ca and CyPA in the exendin-4 group decreased (P<0.05), the atherosclerotic plaque areas of the aorta decreased (P<0.05), the thickening of the aortic wall and the infiltration of inflammatory cells were alleviated significantly, the calcium deposition in the aortic wall was reduced, the positive expression area ratio of RUNX2 and BMP-2, the relative mRNA expression of RUNX2 and BMP-2, the relative protein expression of RUNX2 and BMP-2 in aortic tissue all decreased (P<0.05), and at the same time, the red fluorescence of CyPA expression in aortic tissue was weakened significantly.   Conclusion GLP-1 receptor agonists exendin-4 can inhibit atherosclerosis and vascular calcification in mice, and the mechanism may be related to the reduction of CyPA secretion.

Key words

Atherosclerosis / Glucagon-like peptide 1 receptor agonist / Vascular calcification / Cyclophilin A / Western blotting / Immunofluorescence / Mouse

Cite this article

Download Citations
YANG Shan-shan PAN Yu-xiang ZHENG Wan WANG Zheng. Exendin-4 inhibiting cyclophilin A reducing the pathological phenotype of atherosclerotic mice[J]. Acta Anatomica Sinica. 2024, 55(2): 229-236 https://doi.org/10.16098/j.issn.0529-1356.2024.02.015

References

[1]Fan J, Watanabe T. Atherosclerosis: known and unknown[J]. Pathol Int, 2022, 72(3):151-160.
[2]Li M, Wang ZW, Fang LJ, et al. Programmed cell death in atherosclerosis and vascular calcification[J]. Cell Death Dis, 2022, 13(5):467.
[3]Shen J, Zhao M, Zhang C, et al. IL-1β in atherosclerotic vascular calcification: from bench to bedside[J]. Int J Biol Sci, 2021, 17(15):4353-4364.
[4]Malik F, Li Z. Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: alternative approaches for treatment of Type 2 diabetes[J]. Br J Pharmacol, 2022, 179(4):511-525.
[5]Ferrari F, Scheffel RS, Martins VM, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus and cardiovascular disease: the past, present, and future[J]. Am J Cardiovasc Drugs, 2022, 22(4):363-383.
[6]Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27(4):740-756.
[7]Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential[J]. Int J Biol Sci, 2021, 17(8):2050-2068.
[8]Pahk K, Joung C, Song HY, et al. SP-8356, a novel inhibitor of CD147-cyclophilin A interactions, reduces plaque progression and stabilizes vulnerable plaques in apoE-deficient mice[J]. Int J Mol Sci, 2019, 21(1):95.
[9]Anandan V, Thulaseedharan T, Suresh Kumar A, et al. Cyclophilin A impairs efferocytosis and accelerates atherosclerosis by overexpressing CD 47 and down-regulating calreticulin[J]. Cells, 2021, 10(12):3598.
[10]Liao Y, Luo D, Peng K, et al. Cyclophilin A: a key player for etiological agent infection[J]. Appl Microbiol Biotechnol, 2021, 105(4):1365-1377.
[11]Zhang GL. Research progress in clinical application of GLP-1 receptor agonist [J]. China Urban and Rural Enterprise Health, 2021,36 (4): 31-34. (in Chinese)
张贵龙.GLP-1受体激动剂临床应用研究进展[J].中国城乡企业卫生,2021,36(4):31-34.
[12]Rakipovski G, Rolin B, NØhr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-/- and LDLr-/- mice by a mechanism that includes inflammatory pathways[J]. JACC Basic Transl Sci, 2018, 3(6):844-857.
[13]Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(9 Pt B):2814-2821.
[14]Zhang S, Hong F, Ma C, et al. Hepatic lipid metabolism disorder and atherosclerosis[J]. Endocr Metab Immune Disord Drug Targets, 2022, 22(6):590-600.
[15]Wu Y, Johnson G, Zhao F, et al. Features of lipid metabolism in humanized ApoE knockin rat models[J]. Int J Mol Sci, 2021, 22(15):8262.
[16]Villa-Bellosta R. Vascular calcification: key roles of phosphate and pyrophosphate[J]. Int J Mol Sci, 2021, 22(24):13536.
[17]Wang C, Xu W, An J, et al. Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2[J]. Nat Commun, 2019, 10(1):1203.
[18]Liu L, Zeng P, Yang X, et al. Inhibition of vascular calcification[J]. Arterioscler Thromb Vasc Biol, 2018, 38(10):2382-2395.
[19]Kozu K, Satoh K, Aoki T, et al. Cyclophilin A as a biomarker for the therapeutic effect of balloon angioplasty in chronic thromboembolic pulmonary hypertension[J]. J Cardiol, 2020, 75(4):415-423.
[20]Chang CS, Su SL, Chang CC, et al. Cyclophilin-A: a novel biomarker for untreated male essential hypertension[J]. Biomarkers, 2013, 18(8):716-720.
[21]Ramachandran S, Kartha CC. Cyclophilin-A: a potential screening marker for vascular disease in type-2 diabetes[J]. Can J Physiol Pharmacol, 2012, 90(8):1005-1015.
[22]Xue C, Sowden M, Berk BC. Extracellular cyclophilin A, especially acetylated, causes pulmonary hypertension by stimulating endothelial apoptosis, redox stress, and inflammation[J]. Arterioscler Thromb Vasc Biol, 2017, 37(6):1138-1146.
[23]Su Z, Lin M, Su Y, et al. Oxidized low-density lipoprotein inhibits the degradation of cyclophilin A via the lysosome in vascular smooth muscle cells[J]. Am J Transl Res, 2020, 12(7):3964-3973.

PDF(13105 KB)

Accesses

Citation

Detail

Sections
Recommended

/